https://www.selleckchem.com/pr....oducts/iberdomide.ht
Hemophilia is a high cost low volume disease. Resource limited nations (RLN) usually spend very little on health budget and most of it is spent in dealing with common ailments. Clotting products constitute more than 90% of the total cost of hemophilia care. The manner in which these products can be made accessible for persons with hemophilia (PWH) and how its continuous supply and distribution can be maintained and improved is described in this review. Number of PWH in the Resource Limited Nations (RLN); minimum amount of concentrate
Like
Comment
Share
